FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379094502> ?p ?o ?g. }

• W4379094502 endingPage "105640" @default.
• W4379094502 startingPage "105640" @default.
• W4379094502 abstract "Influenza epidemics and pandemics caused by newly emerging virus strains highlight an urgent need to develop a universal vaccine against viruses. Previously, a monoglycosylated X-181mg vaccine demonstrated that the HA possessing a single N-acetylglucosamine at each N-glycosylation site is superior to confer broader protection in mice than conventional vaccines. However, the greatest challenge in conducting clinical trials is the need to develop robust manufacturing processes capable of producing vaccines at the pilot scale with the desired stability, potency, and efficacy. Whether the monoglycosylated virus vaccine platform can be applied to the new vaccine strain in a timely manner and whether the mass-produced vaccine has the proper immunogenicity to induce cross-protective immunity remains unclear. Here, we show that a pilot-scale manufacturing process produced a monoglycosylated A/Brisbane/02/2018(H1N1) virus vaccine (IVR-190mg) with a single glycan at each glycosylation site of HA and NA. Compared with the fully glycosylated virus vaccine (IVR-190fg), the IVR-190mg provided broader cross-protection in mice against a wide range of H1N1 variants. The enhanced antibody responses induced by IVR-190mg immunization include higher hemagglutination-inhibition titers, higher neutralization activity, more anti-HA head domain, more anti-HA stem antibodies, higher neuraminidase activity inhibition titers, and notably, higher antibody-dependent cellular cytotoxicity. Additionally, the IVR-190mg also induced a more balanced Th1/Th2 response and elicited broader splenic CD4+ and CD8+ T-cell responses than IVR-190fg. This study demonstrated that IVR-190mg produced using a pilot-scale manufacturing process elicits comprehensive cross-strain immune responses that have great potential to substantially mitigate the need for yearly reformulation of strain-specific inactivated vaccines." @default.
• W4379094502 created "2023-06-03" @default.
• W4379094502 creator A5005235378 @default.
• W4379094502 creator A5013548922 @default.
• W4379094502 creator A5014965102 @default.
• W4379094502 creator A5019798190 @default.
• W4379094502 creator A5023462177 @default.
• W4379094502 creator A5023937137 @default.
• W4379094502 creator A5033223037 @default.
• W4379094502 creator A5044758293 @default.
• W4379094502 creator A5059712495 @default.
• W4379094502 creator A5067515188 @default.
• W4379094502 creator A5089819370 @default.
• W4379094502 date "2023-08-01" @default.
• W4379094502 modified "2023-09-27" @default.
• W4379094502 title "Pilot-scale production of inactivated monoglycosylated split H1N1 influenza virus vaccine provides cross-strain protection against influenza viruses" @default.
• W4379094502 cites W1508264729 @default.
• W4379094502 cites W1816587284 @default.
• W4379094502 cites W1968395412 @default.
• W4379094502 cites W1985704471 @default.
• W4379094502 cites W2002632348 @default.
• W4379094502 cites W2002692778 @default.
• W4379094502 cites W2009165647 @default.
• W4379094502 cites W2010937574 @default.
• W4379094502 cites W2040883346 @default.
• W4379094502 cites W2108573701 @default.
• W4379094502 cites W2111366580 @default.
• W4379094502 cites W2117475553 @default.
• W4379094502 cites W2130497622 @default.
• W4379094502 cites W2161738112 @default.
• W4379094502 cites W2164807254 @default.
• W4379094502 cites W2223009545 @default.
• W4379094502 cites W2280670021 @default.
• W4379094502 cites W2417981936 @default.
• W4379094502 cites W2619551885 @default.
• W4379094502 cites W2762703589 @default.
• W4379094502 cites W2775569101 @default.
• W4379094502 cites W2795794761 @default.
• W4379094502 cites W2909919629 @default.
• W4379094502 cites W2918139290 @default.
• W4379094502 cites W2945681432 @default.
• W4379094502 cites W3007714267 @default.
• W4379094502 cites W3042307113 @default.
• W4379094502 cites W3049720826 @default.
• W4379094502 cites W3086796595 @default.
• W4379094502 cites W4214573802 @default.
• W4379094502 cites W4233502330 @default.
• W4379094502 doi "https://doi.org/10.1016/j.antiviral.2023.105640" @default.
• W4379094502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37263355" @default.
• W4379094502 hasPublicationYear "2023" @default.
• W4379094502 type Work @default.
• W4379094502 citedByCount "0" @default.
• W4379094502 crossrefType "journal-article" @default.
• W4379094502 hasAuthorship W4379094502A5005235378 @default.
• W4379094502 hasAuthorship W4379094502A5013548922 @default.
• W4379094502 hasAuthorship W4379094502A5014965102 @default.
• W4379094502 hasAuthorship W4379094502A5019798190 @default.
• W4379094502 hasAuthorship W4379094502A5023462177 @default.
• W4379094502 hasAuthorship W4379094502A5023937137 @default.
• W4379094502 hasAuthorship W4379094502A5033223037 @default.
• W4379094502 hasAuthorship W4379094502A5044758293 @default.
• W4379094502 hasAuthorship W4379094502A5059712495 @default.
• W4379094502 hasAuthorship W4379094502A5067515188 @default.
• W4379094502 hasAuthorship W4379094502A5089819370 @default.
• W4379094502 hasConcept C134164806 @default.
• W4379094502 hasConcept C142724271 @default.
• W4379094502 hasConcept C159047783 @default.
• W4379094502 hasConcept C159654299 @default.
• W4379094502 hasConcept C182072434 @default.
• W4379094502 hasConcept C203014093 @default.
• W4379094502 hasConcept C2522874641 @default.
• W4379094502 hasConcept C2777546802 @default.
• W4379094502 hasConcept C2778692840 @default.
• W4379094502 hasConcept C2779134260 @default.
• W4379094502 hasConcept C2779261636 @default.
• W4379094502 hasConcept C2779308166 @default.
• W4379094502 hasConcept C2779635636 @default.
• W4379094502 hasConcept C2780689484 @default.
• W4379094502 hasConcept C2780868878 @default.
• W4379094502 hasConcept C3008058167 @default.
• W4379094502 hasConcept C32611913 @default.
• W4379094502 hasConcept C524204448 @default.
• W4379094502 hasConcept C71924100 @default.
• W4379094502 hasConcept C86803240 @default.
• W4379094502 hasConcept C89623803 @default.
• W4379094502 hasConceptScore W4379094502C134164806 @default.
• W4379094502 hasConceptScore W4379094502C142724271 @default.
• W4379094502 hasConceptScore W4379094502C159047783 @default.
• W4379094502 hasConceptScore W4379094502C159654299 @default.
• W4379094502 hasConceptScore W4379094502C182072434 @default.
• W4379094502 hasConceptScore W4379094502C203014093 @default.
• W4379094502 hasConceptScore W4379094502C2522874641 @default.
• W4379094502 hasConceptScore W4379094502C2777546802 @default.
• W4379094502 hasConceptScore W4379094502C2778692840 @default.
• W4379094502 hasConceptScore W4379094502C2779134260 @default.
• W4379094502 hasConceptScore W4379094502C2779261636 @default.
• W4379094502 hasConceptScore W4379094502C2779308166 @default.
• W4379094502 hasConceptScore W4379094502C2779635636 @default.

• next